France: Updated ANSM guidelines for determining financial penalties

In brief

In August 2022, the French Agency for the Safety of Health Products (ANSM) published an updated version of its guidelines for determining financial penalties, which will come into effect on 1 October 2022.


In more detail

The ANSM is responsible for monitoring health safety, which allows it to impose penalties to prevent and sanction the actions of operators that fail to comply with their obligations.

Since the entry into force of Law 2011-2012 on 29 December 2011, the ANSM, in cases provided for by the French Public Health Code (FPHC), has the power to impose financial penalties against the authors of breaches.

The level of financial penalties varies according to the nature of the breaches and takes into account, where appropriate, any repetition of the breaches. Depending on the nature of the breach, the maximum amount of the financial penalty imposed may be 10% of the company's turnover for the last financial year (up to a maximum of EUR 1 million), or 30% of the company's turnover for the last financial year for the product or group of products concerned (up to a maximum of EUR 1 million). The sanction may be accompanied by a daily penalty.

To ensure transparency and consistency of its decisions and to guarantee a certain degree of predictability and legibility of the sanction policy carried out, the ANSM had published, as early as 2015, guidelines aimed at explaining how financial sanctions are determined by its services.


  1. A base amount is fixed with respect to the intrinsic nature of the breach.
  2. This base amount is then adjusted with regard to the gravity of the breach, its impact on public health and its duration. It will then be personalized to take into account the company's behavior.
  3. The amount of the sanction thus obtained is finally adjusted, on the one hand, to bring it up to the legal maximum and, on the other hand, to take into account, if necessary, the financial difficulties that may be encountered by the company.

The Social Security Financing Bill for 2020 has strengthened the legislative framework for supply tensions, aimed at preventing shortages of medicines. The legislator has introduced new obligations on marketing authorization holders and pharma companies operating the products (French so-called "exploitant"). For instance, these same companies must have a minimum safety stock of medicines intended for the French market and located on French territory or that of another EU country. New penalties, including financial penalties, have also been adopted to sanction failure to comply with these new obligations.

As a result, in August 2022, the ANSM issued updated guidance, including a specific appendix on the weighting criteria applicable to the breaches of the provisions aimed at preventing shortages of medicines. The importance given to these sanctions is illustrated by the fact that all breaches are associated with the highest base amount (i.e., 20% of the company's turnover for the last financial year for the product or group of products concerned). In addition, in accordance with Article L. 5471-1 of the FPHC, a daily penalty is automatically added. 

Other parts of the ANSM guidelines were not substantially modified; in particular, some clarifications regarding the calculation methods were added.

These updated ANSM guidelines will enter into force on 1 October.

Contact Information

Copyright © 2024 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.